MarketCapExport financials
INmune Bio (INMB)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
INmune Bio Income Statement 2025-2011 | INMB
Brief overview of income trends at INmune Bio
The figures are compared over a five-year interval. INmune Bio reported revenue of $10.9 thousand in 2020 and $50 thousand by 2025. Overall revenue changed by +358%, equal to an annualized rate of about 35.6%. The company expanded its revenue base at a high speed.
EBITDA was −12.2 million dollars at the beginning and −47.3 million dollars at the end of the period (−286.8%). Operating performance weakened relative to revenue. The EBITDA share of revenue changed from −112016.1% to −94598%. The increased EBITDA share is a positive sign.
Net income moved from −12.1 million dollars at the start to −46 million dollars at the end. The negative result deepened, showing weaker final efficiency.
The five-year change in capitalization reached −88%: from $236 million to $28.2 million. The market has not yet confirmed the improvement in fundamentals.
Financial takeaway
The financial trajectory is weak and requires a cautious interpretation. The constructive conclusion rests on revenue expansion and an improving EBITDA margin. Caution is warranted because of declining net profitability, limited operating profitability and lower investor confidence. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement INmune Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
28.2 M | 22.7 M | 211 M | 166 M | 163 M | 236 M | 49.1 M | - | - | - | - | - | - | - | - |
Shares |
24.8 M | 19.9 M | 18 M | 17.9 M | 16.1 M | 12.9 M | 10.3 M | - | - | - | - | - | - | - | - |
Historical Prices |
1.14 | 1.14 | 11.8 | 9.25 | 10.1 | 18.2 | 4.93 | - | - | - | - | - | - | - | - |
Net Income |
-46 M | -42 M | -30 M | -27.3 M | -30.3 M | -12.1 M | -7.68 M | -12.4 M | -831 K | -277 K | - | - | - | - | - |
Revenue |
50 K | 14 K | 155 K | 374 K | 181 K | 10.9 K | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | -10.9 K | - | - | - | - | - | - | - | - | - |
Operating Income |
-47.4 M | -42.6 M | -29.7 M | -26 M | -29.2 M | -12.2 M | -7.76 M | -12.4 M | -981 K | - | - | - | - | - | - |
Interest Expense |
- | 789 K | 2.28 M | 2.01 M | - | 129 K | 77.7 K | - | 150 K | - | - | - | - | - | - |
EBITDA |
-47.3 M | -42.6 M | -29.7 M | -26 M | -29.2 M | -12.2 M | -10.8 M | -12.4 M | -1.13 M | -177 K | - | - | - | - | - |
Operating Expenses |
47.4 M | 42.6 M | 29.9 M | 26.3 M | 29.3 M | 12.2 M | 9.3 M | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
10.3 M | 9.48 M | 9.62 M | 9.26 M | 8.79 M | 6.32 M | 6.02 M | 11.3 M | 546 K | 126 K | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement INmune Bio
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
26.7 M | 26.6 M | 26.6 M | 23.3 M | 22.5 M | 22.3 M | 20.2 M | 19.3 M | 18 M | 18 M | 18 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 17.8 M | 17.3 M | 15 M | 14.3 M | 13.5 M | 12.9 M | 10.8 M | 10.7 M | 10.8 M | 10.8 M | 10.2 M | 9.39 M | 8.72 M | 8.72 M | 8.72 M | 8.55 M | 8.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-1.27 M | -5.41 M | -6.47 M | -24.5 M | -9.74 M | - | -12.1 M | -9.75 M | -11 M | - | -8.56 M | -6.5 M | -6.54 M | - | -7.72 M | -6.84 M | -6.9 M | - | -9.46 M | -6.66 M | -4.56 M | - | -4.72 M | -2.11 M | -2.07 M | - | -3.07 M | -392 K | -1.9 M | - | -1.54 M | -6.17 M | -2.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
50 K | 50 K | 50 K | - | 50 K | - | - | - | 14 K | - | 43 K | 46 K | 38 K | - | 98 K | 16 K | 163 K | - | 14 K | - | 4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-1.48 M | -5.81 M | -7.43 M | -24.6 M | -9.9 M | - | -12.3 M | -9.86 M | -11 M | - | -8.53 M | -6.41 M | -6.42 M | - | -7.44 M | -6.39 M | -6.48 M | - | -9.02 M | -6.55 M | -4.55 M | - | -4.82 M | -2.11 M | -2.09 M | - | -3.08 M | -428 K | -1.91 M | - | -1.54 M | -6.17 M | -2.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | 145 K | 250 K | -8 K | - | 568 K | 631 K | - | - | - | - | - | - | - | - | -8 K | - | 102 K | -395 | 22 K | - | 17.2 K | 36.3 K | 10 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-1.38 M | -5.76 M | -7.4 M | -24.6 M | -9.9 M | - | -12.3 M | -9.86 M | -11 M | - | -8.53 M | -6.41 M | -6.42 M | - | -7.44 M | -6.39 M | -6.48 M | - | -9.02 M | -6.55 M | -4.55 M | - | -4.82 M | -2.11 M | -2.09 M | - | -3.08 M | -428 K | -1.91 M | - | -1.54 M | -6.17 M | -2.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
1.48 M | 5.81 M | 7.43 M | 24.6 M | 9.96 M | - | 12.3 M | 9.86 M | 11 M | - | 8.57 M | 6.46 M | 6.46 M | - | 7.54 M | 6.4 M | 6.64 M | - | 9.04 M | 6.55 M | 4.55 M | - | 4.82 M | 2.11 M | 2.09 M | - | 3.08 M | 428 K | 1.91 M | - | 1.54 M | 6.17 M | 2.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
2.28 M | 2.17 M | 2.55 M | 2.25 M | 2.32 M | - | 2.22 M | 2.81 M | 2.34 M | - | 2.59 M | 2.31 M | 2.33 M | - | 2.38 M | 2.22 M | 2.33 M | - | 2.52 M | 2.09 M | 2.06 M | - | 2.46 M | 357 K | 1.3 M | - | 1.92 M | 1.34 M | 1.3 M | - | 885 K | 5.89 M | 2.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company INmune Bio (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
France
Israel
Australia
Schweiz
Irlanda
